T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H2 2016

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H2 2016
Published Jul 20, 2016
76 pages — Published Jul 20, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H2 2016, provides in depth analysis on T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted pipeline therapeutics.

The report provides comprehensive information on the T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4)
- The report reviews T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics and enlists all their major and minor projects
- The report assesses T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and un

  
Source:
Document ID
GMDHC0407TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) Overview81
Therapeutics Development93
  T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) Products under Development by Stage of Development91
  T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) Products under Development by Therapy Area101
  T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) Products under Development by Indication111
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) Pipeline Products Glance122
  Late Stage Products121
  Early Stage Products131
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) Products under Development by Companies142
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) Products under Development by Universities/Institutes162
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) Therapeutics Assessment187
  Assessment by Monotherapy/Combination Products181
  Assessment by Mechanism of Action192
  Assessment by Route of Administration212
  Assessment by Molecule Type232
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) Companies Involved in Therapeutics Development257
  Biotest AG251
  CEL-SCI Corporation261
  Fountain Biopharma Inc.271
  Immupharma Plc281
  Inovio Pharmaceuticals, Inc.291
  TaiMed Biologics Inc.301
  United Biomedical, Inc.311
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) Drug Profiles3228
  3BNC-117 Drug Profile322
  CEL-1000 Drug Profile342
  forigerimod acetate Drug Profile363
  HIV vaccine 2 Drug Profile391
  ibalizumab Drug Profile402
  ibalizumab biosimilar Drug Profile421
  ibalizumab second generation Drug Profile431
  M-48U1 Drug Profile441
  MAX-16H5 Drug Profile451
  Monoclonal Antibodies to Target CD4 and CD8 for Type 1 Diabetes Drug Profile461
  Monoclonal Antibody Conjugates to Target CD4 and HDAC for HIV-1 Drug Profile471
  Monoclonal Antibody to Inhibit CD4 for HIV Drug Profile481
  Small Molecules to Activate CD4 for HIV Drug Profile491
  Small Molecules to Inhibit CD4 and MHC Class I for HIV Drug Profile501
  Small Molecules to Target CD4 for HIV Drug Profile511
  TMB-360 Drug Profile521
  tregalizumab Drug Profile533
  UB-421 Drug Profile561
  VRC-01 Drug Profile573
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) Dormant Projects604
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) Discontinued Products641
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) Featured News &Press Releases6510
  Jun 07, 2016: First European Patients Commence Dosing In Lupuzor's Pivotal Phase III Study651
  May 24, 2016: Theratechnologies Announces that 82.5% of Patients Achieved the Primary Endpoint in the Phase III Ibalizumab Trial651
  May 06, 2016: Antibody therapy opens door to potential new treatment for HIV661
  May 05, 2016: Broadly neutralizing antibodies improve immune response; clear HIV reservoirs671
  Apr 27, 2016: Theratechnologies Announces Completion of Enrollment for Phase III Ibalizumab Trial681
  Apr 27, 2016: Single Antibody Infusions Provide Durable Protection Against HIV-Like Virus in Monkeys681
  Mar 09, 2016: First European site opened in France and patient recruitment commences in Lupuzor pivotal phase III study691
  Feb 15, 2016: First US Patients Commence Dosing In Lupuzor Pivotal Phase III Study701
  Dec 15, 2015: Over 70 Lupus Specialists Gather in Paris for Lupuzor s Phase III Investigators Meeting701
  Dec 07, 2015: Lupuzor Pivotal Phase III Trial Recruiting First US Lupus Patients711
  Nov 09, 2015: Biotest to present data from TREAT 2b trial at The American College of Rheumatology 2015 Annual Meeting711
  Nov 04, 2015: ImmuPharma Provides Lupuzor Phase III Pivotal Trial Update721
  Jul 27, 2015: Clinicaltrials.Gov Registration Of Lupuzor Pivotal Phase III Trial731
  Jun 25, 2015: Lupuzor's Founder, Dr Slyviane Muller - Awarded Medal of Innovation from CNRS for Lupuzor731
  Apr 24, 2015: Biotest AG: Biotest Phase IIb study of Tregalizumab (BT-061) in moderate to severe rheumatoide Arthritis did not meet the primary endpoint - potential one time effect of up to - EUR 30 million741
Appendix752
  Methodology751
  Coverage751
  Secondary Research751
  Primary Research751
  Expert Panel Validation751
  Contact Us751
  Disclaimer761

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/T-Cell-Surface-Glycoprotein-CD4-T-Cell-Surface-Antigen-T4-Leu-3-or-CD4-Pipeline-Review-H2-2016-2088-16289>
  
APA:
Global Markets Direct - Market Research. (2016). T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/T-Cell-Surface-Glycoprotein-CD4-T-Cell-Surface-Antigen-T4-Leu-3-or-CD4-Pipeline-Review-H2-2016-2088-16289>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.